Clinical Trial Update: Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study of TAK-117 (MLN1117) in subjects with advanced metastatic solid tumors; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• TAK-117

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Metastatic Solid Tumors | Phase 1 | Status: COMPLETED | Results posted: 2017-03-09